NPN & NHP regulatory FAQ.

We normally start with holder contact details, the formula (medicinal and non-medicinal ingredients), dosage form and recommended dosage, intended claims, a draft label, relevant product documents and the site-licence information for the manufacturer, packager or importer.

Support can include classification assessment, evidence review, documentation preparation, label review, submission management, Health Canada correspondence, IRN responses and post-approval amendment or notification planning.

Requirements depend on the product and claims. Health Canada may expect finished-product potency, purity and identity testing, microbial testing, heavy-metals testing and stability data. Class I products that fully follow an applicable monograph may need less extensive evidence than more complex Class II or III products.

Timing depends on application class, product complexity and how complete the materials are before filing. Preparation time also depends on how quickly product information and supporting evidence can be assembled. Health Canada controls its own review timing.

Natural health products marketed in Canada need a valid NPN issued by Health Canada. This applies to Canadian and international sellers supplying the Canadian market; products without an NPN may face compliance action or listing removal.

Canadian requirements differ from other markets. Classification, monograph selection, evidence structure, bilingual labelling and IRN responses all affect whether a submission is accepted and how efficiently it moves forward.

The NPN is issued to the licence holder responsible for the product in Canada. Depending on the structure, that can be the importer, distributor or brand owner rather than the manufacturer. International businesses often need an appropriate Canadian licensing structure.

An NPN has no fixed expiry date, but it can become invalid when licensed details change without the required filing, GMP obligations are not maintained, or Health Canada identifies a compliance concern.

Significant changes—such as medicinal ingredients, potency, recommended dosage, risk information or specifications—can require an amendment before implementation. Some lower-risk changes may be reported by notification within the applicable timeframe.

Health Canada review targets vary by class and submission complexity. A complete, well-prepared application is the best way to reduce avoidable delays and Information Requests.

Class I products generally follow an applicable Health Canada monograph. Class II applications may rely on published studies, traditional-use evidence or pharmacopeial standards. Class III applications require a more robust safety and efficacy evidence package.

Health Canada sets its own review timelines. We focus on what can be controlled: identifying the most efficient pathway, resolving issues before filing, preparing complete materials and responding promptly to regulator questions.

No. Canadian NHP labels have their own required bilingual content, terminology, NPN display, directions, cautions and ingredient presentation. A Canadian compliance review and usually a label redesign are needed before marketing.

No. Medicinal ingredients must be individually declared with their specific quantities per dosage unit; a proprietary-blend presentation is not permitted for Canadian NHP labelling.

Yes. Mandatory information must appear in English and French, including product name and recommended use, ingredients, dosage directions, cautions, storage details and the licence-holder information.

Products manufactured in Canada do not need an importer for Canadian distribution, but the facility must hold the appropriate NHP Site Licence and operate under GMP. Imported products require a Canadian importer with the relevant licensed import activity.